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Abstract
Background: Mutation analysis of KIT and PDGFRA genes in gastrointestinal stromal tumors is gaining increasing 
importance for prognosis of GISTs and for prediction of treatment response. Several groups have identified specific 
mutational subtypes in KIT exon 11 associated with an increased risk of metastatic disease whereas GISTs with PDGFRA 
mutations often behave less aggressive. Furthermore, in advanced GIST disease with proven KIT exon 9 mutation the 
doubled daily dose of 800 mg imatinib increases the progression free survival and is now recommended both in the 
European and the American Guidelines. In Germany, there are still no general rules how to perform mutational analysis.
Methods: When comparing results from six different molecular laboratories we recognized the need of 
standardisation. Six German university laboratories with experience in mutation analysis in GISTs joined together to 
develop recommendations for the mutation analysis of the most common and clinically relevant hot spots, i. e. KIT 
exons 9 and 11 and PDGFRA exon 18. We performed a three-phased interlaboratory trial to identify pitfalls in 
performing molecular analysis in GISTs.
Results: We developed a design for a continuous external laboratory trial. In 2009 this external trial was conducted by 
19 laboratories via the initiative for quality assurance in pathology (QuiP) of the German Society of Pathology and the 
Professional Association of German Pathologists.
Conclusions: By performing a three-phased internal interlaboratory trial and conducting an external trial in Germany 
we were able to identify potential pitfalls when performing KIT and PDGFRA mutational analysis in gastrointestinal 
stromal tumors. We developed standard operation procedures which are provided with the manuscript to allow other 
laboratories to prevent these pitfalls.
Background
Gastrointestinal stromal tumors (GISTs) represent the
most common mesenchymal tumors of the gastrointesti-
nal tract. About 50% of GISTs behave clinically aggres-
sive. Since 2001, treatment options have dramatically
improved with the introduction of tyrosine kinase inhibi-
tors. On the molecular level, the vast majority of tumors
carries activating mutations in the KIT gene or the PDG-
FRA (platelet derived growth factor receptor alpha) gene,
both genes encoding closely related type III tyrosine
kinases. The relevance of the mutational status in these
genes both for clinical prognosis and for prediction of
response to treatment has been increasingly recog-
nized[1,2]. Mutational analyses are now performed in
many laboratories worldwide and several protocols have
been published. Given the high impact on clinical deci-
sions, mutational testing should meet the highest stan-
dard for quality assurance.
The reported frequencies of mutated sites differ con-
siderably between anatomic locations of tumors and
depend on the setting of calculation (e.g., population
based study vs. results of clinical trials)[3,4] but also on
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technical issues. Primary activating mutations occur in
the extracellular parts of the receptor protein (i.e., KIT
exon 9), in the juxtamembrane domain (KIT  exon 11,
PDGFRA exon 12), in the first tyrosine kinase domain
(KIT  exon 13, PDGFRA  exon 14) or in the second
tyrosine kinase domain (KIT exon 17, PDGFRA exon 18).
As a strongly simplified rule one can suppose that about
65% of all GISTs harbour primary KIT exon 11 mutations,
whereas  KIT exon 9 and PDGFRA  exon 18 mutations
account each for about 10% of primary mutations. Thus,
about 85% of all GISTs carry a mutation at one of these
three sites. Approximately 10% of GISTs are so-called
wildtype GISTs without any detectable mutations in the
known hot spots. The remaining 5% may carry mutations
in the exons 13 or 17 of KIT or in exons 12 or 14 of PDG-
FRA, so the frequency in each of these regions is below
1% [5,6]. For these latter regions there is no experience
concerning their prognostic and predictive value, there-
fore we decided to restrict our study to the most impor-
tant and clinically relevant exons, i. e. KIT exons 9 and 11
and PDGFRA exon 18.
Since fresh frozen tumor tissue is only rarely available
for mutational testing, formalin-fixed and paraffin-
embedded tissue (FFPE) is widely used for molecular
analyses. The integrity and stability of DNA in FFPE is
the limiting factor for the reliability of mutational testing
[7]. DNA quality depends predominantly on the manner
and duration of fixation and the age of paraffin blocks.
Our results have been generated by Sanger sequencing
as in our view, it remains to date the gold standard for
mutational analysis of KIT and PDGFRA and is already
available in nearly all places. Denaturing high-pressure
liquid chromatography (DHPLC) as used successfully by
some other laboratories[2] is a screening technique which
has to be followed by direct sequencing as it cannot pre-
dict the precise sequence of the highly variable KIT and
PDGFRA mutations occurring in GISTs. DHPLC is not
available in all places due to high costs for the technical
equipment. Next generation sequencing systems that
work with pyrosequencing techniques or mass-spectros-
copy are at the moment not suited for routine mutation
analysis because they are designed for high-throughput
sequencing, still too expensive and not widely available.
We aimed to analyze all steps of mutational testing,
beginning with DNA extraction from FFPE samples up to
the correct reporting of mutations to develop standard
operation procedures suitable for every laboratory willing
to establish sequence analysis. Therefore we compared
the analysis methods of six German university laborato-
ries. In a first step, the participating laboratories exam-
ined the reliability and comparability of KIT exon 9 and
11 and PDGFRA exon 18 mutation testing using a set of
10 DNA samples extracted from FFPE tissue. Second, to
consider the heterogeneity of tissue blocks from different
sources, a set of 12 tissue blocks collected from the par-
ticipating laboratories was analyzed. The third step
served for the detection of the ideal primer combinations
for mutation analysis in the different hot spots. In all
steps of the internal trial, each of the participating labora-
tories used its own protocols. By standardizing the meth-
ods as a result of the different trial steps, a high degree of
interlaboratory concordance could be achieved.
Besides the results of our trial, we here present a cross-
validated protocol for testing and reporting the most
common mutations in GISTs. Additionally, the results of
an external trial for other laboratories are presented
underlining the need of our initiative.
Results
First trial (mutation analysis from extracted DNA)
The results for the mutation analysis as provided by the
panel labs are shown in detail in Table 1. All results were
returned within the time limit. The sequence data
obtained by Lab A at a previous and the actual analysis
were supposed to be the nominal results; in case of vari-
ance compared to the other panel labs the data were rean-
alyzed and adjusted (as for sample T1.4).
For five out of 10 samples (T1.2, T1.5, T1.7, T1.8 and
T1.9), all six laboratories achieved identical assessments.
In five samples, conflicting data were obtained by at least
one of the panel labs. For these samples, the reported
data were compared to the corresponding sequence elec-
tropherograms first. In one sample (T1.1) the divergent
mutation data on KIT exon 11 obtained by two labs could
be clarified by re-evaluation of the electropherograms.
Concerning the samples T1.3, T1.6 and T1.10, there was
accordance in five labs, one lab each failed to detect the
mutation in KIT exon 11 or PDGFRA exon 18 due to high
background peaks (Fig. 1a). Evaluation of mutation data
in sample T1.4 was more complex: three labs achieved
identical results concerning PDGFRA exon 18, in Lab A
the electropherogram was incorrectly evaluated (Fig. 1b),
and two labs reported a false mutation. In Lab D, reampli-
fication lead to the pretended change p.R822 H in PDG-
FRA exon 18 (Fig. 1c). Lab E reported a mutation in KIT
exon 11. This was the only example for the allocation of a
mutation to a wild-type exon; all other wild-type
sequences were judged correctly.
Taken together, analysis of KIT exon 11 failed in three
cases, including two cases with the detection of wild-type
sequences instead of point mutation and duplication,
respectively, and one case with the description of a dele-
tion instead of wild-type. The mutational status of PDG-
FRA exon 18 was described falsely in four cases including
the detection of wild-type sequences instead of the point
mutation D842V and two deletions. In one case, a point
mutation was detected instead of deletion.Merkelbach-Bruse et al. BMC Medical Genetics 2010, 11:106
http://www.biomedcentral.com/1471-2350/11/106
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The discrepancies in mutation analysis from extracted
DNA samples had several reasons: First the interpreta-
tion of electropherograms had not been discussed prior
to the trial, nor were there rules how to report the results.
Second, some labs had difficulties in detection mutations,
especially point mutations due to high background in
their electropherograms. Third, in one lab reamplifica-
tion led to a false-positive result in PDGFRA exon 18.
Second trial (mutation analysis from FFPE material)
As detailed in additional files 1, 2, 3 and 4 each of the
panel labs followed its own extraction protocol. The qual-
ity of DNA extracts was assessed by agarose-gelelectro-
phoresis which is shown exemplarily for Lab A in Fig. 2.
All samples showed the typical DNA-smear with samples
T2.5 and T2.10 containing only strongly fragmented
DNA and samples T2.2 and T2.4 indicating very low
amounts of high-molecular weight DNA. The amount of
DNA required for amplification was estimated individu-
ally by each panel lab.
The results of the mutation analysis as provided by the
panel labs are shown in detail in Table 2. All panel labs
met the deadline for reporting the results. Except for
Table 1: Nominal and actual results of the mutation analyses of KIT exons 9 and 11 and PDGFRA exon 18 performed in trial 1.
sample exon nominal result Lab A Lab Ba Lab Ca Lab D Lab Ea Lab F
T1.1 KIT 11 c.1670_1675del6
p.W557_V559delins
F
p.W557_K558del p.W557_V559del
T1.2 KIT 9 c.1510_1515dup6
p.A502_Y503dup
T1.3 KIT 11 c.1714_1740dup27 c.wild-type
p.D572_H580dup p.wild-type
T1.4 KIT 11 c.wild-type c.1690_1692del
p.wild-type p. N564del
PDGFRA 18 c.2527_2538del12 c.wild-type c.2464G>A c.wild-type
p.I843_D846del p.D842_H845del p.wild-type p.R822H p.wild-type
T1.5 KIT 9,11 c.wild-type
PDGFRA 18 p.wild-type
T1.6 PDGFRA 18 c.2525A>T c.wild-type
p.D842V p.wild-type
T1.7 KIT 9,11 c.wild-type
PDGFRA 18 p.wild-type
T1.8 KIT 9,11 c.wild-type
PDGFRA 18 p.wild-type
T1.9 KIT 9,11 c.wild-type
PDGFRA 18 p.wild-type
T1.10 KIT 11 c.1676T>A c.wild-type
p.V559D p.wild-type
Only the nominal results of the relevant exons are given, other exons are wild-type; for the individual panel labs only the actual results differing 
from the nominal results are denoted on DNA and protein level; matching results are not shown.
a changes in DNA sequence were not specified in Labs B, C and EMerkelbach-Bruse et al. BMC Medical Genetics 2010, 11:106
http://www.biomedcentral.com/1471-2350/11/106
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Figure 1 Sequence details illustrating the divergent results of the first trial. a Detail of the forward sequencing reaction of sample T1.6: the mis-
sense mutation c.2525A>T leading to p.D842V in PDGFRA was not detected due to high background peaks. b Detail of the forward reaction of sample 
T1.4: the deletion c.2527_2538del12 in PDGFRA was misinterpreted as p.D842_H845del instead of p.I843_D846del. c Detail of the forward reaction of 
sample T1.4: Reamplificaton lead to the assumption of an unknown missense mutation in PDGFRA (c.2464G>A leading to p.R822H). Mutated nucle-
otides are marked by open boxes.Merkelbach-Bruse et al. BMC Medical Genetics 2010, 11:106
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sample T2.4 and T2.10 the results of the majority of the
panel labs were defined as nominal sequence data. For
these two samples the sequence data obtained on frozen
tissue by Lab B and Lab E who provided the correspond-
ing tissue blocks were supposed to be the nominal results.
In three out of 12 samples (T2.3, T2.5 and T2.6), the
accurate mutation was found and described correctly by
all panel labs. In another three samples (T2.2, T2.9 and
T2.11), the accurate mutation was found but reported
falsely by at least one lab (sample T2.11) and at most by
three labs (sample T2.2). In sample T2.9, only the three
different descriptions given by Lab A, Lab B and Lab D
were applicable.
In four out of 12 samples a wrong mutation or a wild-
type sequence was reported by one (sample T2.1 and
T2.12) or two labs (sample T2.7 and T2.8). The allocation
of wild-type instead of mutation was most often observed
in case of point mutations.
The remaining two samples (T2.4 and T2.10) yielded
rather controversial results. The DNA extracted from
these samples was either not amplifiable or generated
wild-type sequences or even false mutations due to con-
taminations by other DNA samples. Sequence analysis
done on DNA extracted from frozen tissue at a later date
was successful in all of the panel labs (data not shown). In
the second trial all wild-type sequences were judged cor-
rectly.
Taken together, six samples were assessed as wild-type
instead of mutation, including two point mutations, three
deletions and a duplication. In three samples, a wrong
mutation was assigned. This was probably due to con-
tamination or confusion of samples, as all these muta-
tions occurred in other samples of our probe set.
In addition to the results of the first trial, the second
trial showed that special attention has to be paid to DNA
quality and to samples with an underrepresentation of
wild-type or mutated sequences. The possibility of con-
tamination has to be taken into account.
Third trial (comparison of different primer sets for KIT exon 
11)
Three different DNA samples containing mutations in
KIT  exon 11 (i.e. two deletions, c.1735_1737delGAT;
p.D579del and c.1661_1705del45bp; p.E554_Y568del and
one duplication, c.1728_1766dup39bp; p.L576_L588dup)
were analyzed. Each of the participating laboratories
amplified the DNA from these samples only with four dif-
ferent primer sets for KIT  exon 11 (Additional file 4,
Table AF 2 in the additional files), because the primer
pairs used in Lab A and B and Lab C and D were identi-
cal, respectively.
The amount of DNA required for amplification was
estimated individually by each panel lab. All results were
reported within the time limit and are detailed in Table 3.
Each lab provided a judgement of amplification and
sequencing quality for all primer/sample combinations.
All approaches with technically successful performance
of amplification and sequencing yielded the expected
results.
Exemplarily, the amplification products generated in
Lab D are shown in Fig. 3. Clear bands for all three sam-
ples were observed only in amplification reactions using
primer combinations A/B-11 and C/D-11 thereby the
bands for the former were rather faint. Amplification
with primer pair E-11 resulted in synthesis of primer
dimers in each reaction. In sample T3.3, which carries a
large duplication in KIT exon 11, a clearly visible DNA
smear with a larger size than the PCR products could be
noticed. Primer pair F-11 produced unspecific fragments
sized between 200 and 250 base pairs. With 294 bp, this
primer pair amplifies the largest fragment of KIT exon 11.
Taking together all approaches to amplify the DNA sam-
ples with each primer/sample combination in the five
panel labs the amplification with primer pair E-11 failed
in three instances. Unspecific bands were observed in
several PCR products generated with primer pair F-11
but the quality was always sufficient to continue with the
next experimental step.
The amplification results were reflected by the
sequencing results: in each panel lab all sequencing reac-
tions carried out with primer combinations A/B-11 and
C/D-11 were successful. Altogether the sequencing reac-
tion of PCR products generated with primer pair E-11 or
primer pair F-11 ended without result in seven or six
cases, respectively. This was mainly due to the location of
these two primer pairs. The forward primer used in Lab F
is too far upstream of the exon-intron boundary resulting
in faint fluorescence signals in the end of the analyzed
fragment and is therefore not suitable for the detection of
distal mutations. Unlike primer pair F-11, primer pair E-
11 generates the smallest KIT exon 11 fragment in this
trial, where the forward primer is located right in the
Figure 2 1% gelelectrophoresis of DNA extracts prepared for the 
second trial. M: DNA length standard λ/Eco130I (Fermentas, St. Leon-
Roth, Germany).M
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Table 2: Nominal and actual results of the mutation analyses of KIT exons 9 and 11 and PDGFRA exon 18 performed in trial 2.
sample exon nominal result Lab A Lab B Lab Ca Lab D Lab Ea Lab F
T2.1 11 c.IVS10(-5)_(-1);
1648_1672del30 p.Q567_577Pdel
p.K550_558del
T2.2 18 c.2528_2539del12 c.2530_2538del9
p.I843T; p.I843_S847insT p.I843_S847del
M844_S847del
T2.3 11 c.1669T>A
p.W557R
T2.4 11 c.1712_1738dup27 c.b c.b c.wild-type c.b
p.H580L; p.b p.b p.wild-type p.insLDPTQLPYD p.D572_H580ins p.b
D572_H580dup
T2.5 11 c.1727T>C
p.L576P
T2.6 c.wild-type
p.wild-type
T2.7 11 c.1669T>A p.W557_R558del c.wild-type
p.W557R p.wild-type
T2.8 11 c.1679T>A c.wild-type c.1811T>A
p.V560D p.wild-type p.V604D
T2.9 11 c.c c.1693_1716del24; c.1693_1720del28; c.1692_1720del
1720del insC p.G565P; p.G564_D572del p.G565_D572del
p.c p.G565_D572del; p.G565_T574delinsP N566_T574del p.G565_P573del
T774del
T2.10 11 c.1668_1723del57d c.1679T>A c.1672_1716del45 c.wild-type c.wild-type c.wild-type
p.W557_Q575deld p.V560D p.K558_D572del p.wild-type p.wild-type p.wild-typeM
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T2.11 11 c.1669_1674del6
p.W557_K558del p.W557_R558del
T2.12 11 c.1676T>A
p.V559D p.W557_R558del
Only the nominal results of the relevant exons are given, other exons are wild-type; for the individual panel labs only the results differing from the nominal results are denoted on DNA and protein 
level, matching results are not shown.
a changes in DNA sequence were not specified in Lab C and E
b in Lab A and Lab F the DNA was not amplifiable; in Lab B mutation was detected from frozen tissue
c complex deletion, different specifications are possible (see Lab A, Lab B and Lab C)
d mutation could not be detected from FFPE material in the second trial; in Lab E mutation was detected from frozen tissue
Table 2: Nominal and actual results of the mutation analyses of KIT exons 9 and 11 and PDGFRA exon 18 performed in trial 2. (Continued)M
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Table 3: Results of the mutation analyses of KIT exon 11 performed in trial 3.
Lab A Lab C Lab D Lab E Lab F
Sample T3.1 T3.2 T3.3 T3.1 T3.2 T3.3 T3.1 T3.2 T3.3 T3.1 T3.2 T3.3 T3.1 T3.2 T3.3
E x p e r i m e n t a l  S t e p A S A S A S AS AS AS AS AS AS AS AS AS AS AS AS
P r i m e r  L a b  A / B + + + + + + + ++ ++ ++ + + + + + + + + + + + / - + + + + + +
P r i m e r  L a b  C / D + + + + + + + ++ ++ ++ + + + + + + + + + + + / - + + + + + +
Primer Lab E +/- - +/- - +/- - - - - - - - + + + - + +/- + + + + + +/- + +/- + +/- + +/-
P r i m e r  L a b  F + / - -+ + + + / - + ++ ++ ++ -+ + + - + -+ + + - + - + + + +
For each lab the result of amplification (A) and sequence analysis (S) is detailed. "+" means success of amplification or nominal result in sequence analysis, "+/-" means only faint amplification with 
unspecific extra-bands or different/not-scorable sequence-analysis, and "-" means failure of amplification or sequence analysis. Primer pairs used in Lab A and B and Lab C and D were the same, 
respectively. Lab B did not participate in the third trial suppl.Merkelbach-Bruse et al. BMC Medical Genetics 2010, 11:106
http://www.biomedcentral.com/1471-2350/11/106
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beginning of KIT exon 11 and therefore not suitable for
detecting mutations in this region (data not shown).
Discussion
The detection of common KIT and PDGFRA mutations
in GIST is implicated in diagnosis, prognosis, therapy
decisions and prediction of response to treatment. Sev-
eral studies have shown that GISTs are characterized by a
strong genotype-phenotype correlation[4]. Among many
different types of the heterogenous KIT exon 11 muta-
tions, for example, p.W557_K558del indicates a more
aggressive clinical behaviour[8,9]. On the other hand,
substitutions and duplications at the 3'-end of KIT exon
11 are considered to be associated with a clinically less
aggressive phenotype[10,11]. In KIT exon 9 almost exclu-
sively a single type of mutation occurs, i.e.,
p.A502_Y503dup, and about 90% of KIT exon 9 mutated
tumors are located in the small bowel and have a spindled
phenotype. These tumors have initially been considered
to be at high risk for a malignant course[10,11]. Recent
studies have put this conclusion into question[4]. On the
other hand, GISTs with PDGFRA exon 18 mutations are
predominantly gastric tumors with an epithelioid mor-
phology. Among the heterogeneous types of mutations,
the point mutation p.D842V is by far the most common.
This special type as well as other point mutations and
several in frame-deletions are associated with a favour-
able prognosis[12-14].
The best response to imatinib (standard dose: 400 mg
daily) is achieved by GISTs with KIT-exon 11 mutations
regardless of the type of genomic alteration[1,2]. A very
important purpose of mutational analysis of GISTs for
treatment options is the detection of KIT exon 9 mutants,
as several studies have shown that the response rates are
significantly improved by applying a higher imatinib dose
(800 mg daily)[1,2]. Furthermore, p.D842V, the most
common PDGFRA mutation, is associated with a primary
resistance to imatinib due to structural alterations of the
imatinib binding pocket[15]. However, other types of
PDGFRA exon 18 mutations may respond well to ima-
tinib[6].
For rare cases of negative or ambiguous CD117 (KIT)
immunostaining, sequencing of KIT and PDGFRA can be
used for differential diagnosis[16]. The major purpose of
mutational analysis is, however, prognostication of the
clinical course and prediction of the response to treat -
ment with imatinib, which represents the first line ther-
apy in metastastic and advanced GIST disease[1,2]. In
inoperable primary lesions, neoadjuvant treatment may
be an option to achieve secondary operability[17]. Very
recent studies show the efficacy of an adjuvant treatment
in completely R0-resected GISTs to increase progression-
free survival[18]. Especially in the adjuvant setting, it may
become increasingly important to exclude patients
expected to have a mutation leading to a primary resis-
tance to imatinib. Therefore, it is indispensable to estab-
lish standardized methodological approaches for sample
preparation and sequence analysis as well as for reporting
and interpretation of data.
The interlaboratory three-step trial presented here
shows on the one hand a high accordance in mutation
testing between the six panel labs but on the other hand
sources of error occurring in different methodological
s t e p s .  I t  i s  v e ry  i m p o r t a n t  t o  r e c o g n i z e  t h e s e  p o s s i b l e
sources of mistakes because of the pivotal role of muta-
tional testing for prognosis and treatment of the individ-
ual patient. Summarizing the results of our different trial
steps several levels of possible pitfalls can be identified -
the practical ones concerning technical procedures and
the theoretical ones relevant for data interpretation:
The quality of DNA extracted from FFPE tissue blocks
is affected mainly by degradation of target DNA due to
the reaction of the phosphodiester backbone with forma-
lin and by the copurification of inhibitory substances as
for instance hemoglobin[19]. Some of the parameters
which influence the degradation of DNA at the stage of
tissue fixation are well known, e.g. the age of specimens,
the fixative and the duration of fixation[20,21]. In prac-
tice however, these parameters are highly variable, partic-
ularly if the material is received from different institutes.
The differing results from two samples in our second trial
(T2.4 and T2.10) underline the importance of adequate
fixation. Our suggestion for optimal fixation is (as pub-
lished also by others[22,23]) to use 4% buffered formalin
for biopsies at least 6 hours, for larger specimens over-
night. One major goal of the extraction protocol must be
to preserve the DNA as good as possible with a gentle
procedure. The different extraction methods the six labs
used all proved to be suitable (see Additional files 1, 2 and
4, Methods AF 1.1., AF 2.3. and Table AF 1).
Excess target DNA within a PCR mixture can inhibit
the reaction and lead to false negative results due to non-
productive target-target interaction[24]. Therefore it is
important to assess the DNA amount and the extent of
degradation for each sample. For this purpose we highly
Figure 3 3% gelelectrophoresis of the PCR products amplified 
from the third-trial samples. Amplifications were performed with 
four different primer pairs in Lab D. The amplification was done using 
an annealing temperature of 60°C for each primer set. M: DNA length 
standard Gene Ruler 50 bp (Fermentas, St. Leon-Roth, Germany).Merkelbach-Bruse et al. BMC Medical Genetics 2010, 11:106
http://www.biomedcentral.com/1471-2350/11/106
Page 10 of 14
recommend to use agarose gelelectrophoresis. Unlike the
spectrophotometric measurement it allows also the
assessment of DNA integrity. Because the PCR result
depends on the number of amplifiable fragments it
should be avoided to use standard DNA amounts as PCR
template. It is strongly recommended not to analyze sam-
ples with bad DNA quality. In such cases, additional
material (e.g. fresh frozen tissue, if available, or another
paraffin block) should be used (see also Additional file 1,
Methods AF 1.2.).
Next, the steps of amplification and cycle sequencing
implicate some obstacles in generating the correct muta-
tion data. The number of PCR cycles should not exceed
40 as increasing the cycle number can lead to a compen-
sation of poor quality DNA but also increases the risk of
amplifiying contamination DNA fragments [25]. It was
also shown that reamplification should be avoided even
in case of low amounts of PCR products. Reamplification
can lead to PCR artifacts and therewith to false allocation
of point mutations. One possibility to increase the sensi-
tivity may be the application of nested PCR. However,
this additional step prolongs the work-up of tumor sam-
ples. If amplification failed twice, the analysis should be
stopped at this point. The analysis can be re-tried with
another paraffin block (see also Additional files 1 and 2,
Methods AF 1.3., AF 2.4.).
The design of the primers in the different genomic
regions is another important issue. Too large fragments
lead to problems especially in formalin-fixed material.
The optimal distance of the forward primer to the exon-
intron boundary should be considered in designing the
primers. Otherwise mutations in the 3' region or the dis-
tal region can hardly be detected either due to high back-
ground in the beginning of electropherograms or faint
fluorescence signals in the end of the reaction. From the
results of our third trial, we decided to recommend two
primer pairs for amplification of KIT exon 11 which are
shown in Additional file 4, Table AF 2.
For the other most frequently mutated exons, i. e. PDG-
FRA exon 18 and KIT exon 9, several observations of the
different labs have to be considered before choosing the
primer design. In sequencing PDGFRA exon 18, it has to
be taken into account, that in 11,5% of samples (data not
shown) an intron polymorphism (c.2440 - 49delA) can be
found. The forward primer can either bind in front of or
behind this polymorphism. Whereas in the former case
sequence interpretation may be difficult due to interfer-
ence of sequences, in the latter case the forward primer
binds very close to the exon-intron-boundary. Depending
on the experience in evaluating sequence data each labo-
ratory has to decide independently which primer design
is chosen.
For  KIT  Exon 9 the most frequent mutation
p.A502_Y503dup can be evaluated specifically by a
shorter 146-bp fragment (as done for example by Lab A
referred to as primer pair A-9) from the distal region[10].
By this procedure also the mutation p.F506_F508dup and
the complex deletion p.E490_F504del found only once
can be detected[26,27]. Alternatively, a primer design
including the whole exon 9 can be used detecting also
rarely occurring point mutations, e.g. p.P456 S and even-
tually p.F469L, p.N486 D and p.V489A, which were to
date only detected in Ewing sarcoma[28,29]. It has to be
kept in mind, that this primer pair generates a fragment
of 310 bp in length. Depending on the degree of DNA
fragmentation, it may be difficult to amplify this frag-
ment.
A standard protocol for amplification with the recom-
mended primer pairs in all three exons is provided as
additional files to the manuscript (see also under addi-
tional files 2 and 4, AF 2.4. and Table AF 2).
Interpretation of electropherograms should be done
carefully. It is indispensable to analyze not only the base-
sequence given by the sequence analysis programs but
also to check the electropherograms as many point muta-
tions are underrepresented and thus are easily missed. All
wild-type sequences evaluated by eye should be re-ana-
lyzed by using an alignment program like "BLAST" (basic
local alignment search tool; http://blast.ncbi.nlm.nih.gov/
Blast.cgi) to detect homozygous mutations which are eas-
ily overlooked in the electropherograms. Mutations
should be described according to the standard of the
human genome variation society (HGVS)[30]. A compre-
hensive catalogue of published KIT and PDGFRA muta-
tion data are available at http://www.sanger.ac.uk/perl/
genetics/CGP/cosmic?action=gene&ln=KIT and http://
www.sanger.ac.uk/perl/genetics/CGP/cos-
mic?action=gene;ln=PDGFRA (see also in the additional
files 2, 3 and 4, AF 2.5., 3 and Table AF3).
As the results of mutational analyses are the basis of
comprehensive clinical decisions, suggestions for report-
ing the results of mutation analysis are given in Table 4.
Thus, these results need to be reported by an experienced
pathologist in the context of clinical and histopathologi-
cal findings. Pathologists and clinicians should ensure
that the reports are properly transferred to the responsi-
ble physicians. The report should at least include a state-
ment on the individual risk of a given patient and should
assess the molecular finding for the therapeutic options.
The results in our internal interlaboratory trials under-
line that false-positive and false-negative results in muta-
tion analysis may occur even in laboratories with some
experience in this field. The consequences of these mis-
takes may be dramatical for patients. A false-negative
wild type sequence in KIT exon 11 in a tumor habouring
a mutation in this region could result in a wrong assess-
ment of treatment response and for example to the
change of therapy. For the imatinib-resistant point muta-Merkelbach-Bruse et al. BMC Medical Genetics 2010, 11:106
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tion in PDGFRA exon 18, tumors in which this mutation
was missed to insufficient methodology may be treated
with imatinib without any positive effect. The same holds
true for treatment prediction in cases with false-positive
results.
In order to check the quality of external mutation anal-
yses which are now performed in an increasing number
of laboratories, we decided to design an external trial
being available via the initiative for quality assurance in
pathology (QuiP) of the German Society of Pathology and
the Professional Association of German Pathologists. The
first results of this external trial underline the need of fur-
ther activities in these areas as only 11 of the 19 partici-
pants were able to perform the trial successfully. Five of
the eight institutions that failed ordered a new test set in
the mean-time. Four of them succeeded in the repetition,
in the remaining institution the second round of the
external trial is still in progress.
Summarizing the results of the three inter-laboratory
trials, the discussions at our four panel meetings and the
results of our external trial, we developed a proposal for
the mutation testing procedure which is available as addi-
tional files. We decided to propose not only one method
b u t  i n  s o m e  s t e p s  s e v e r a l  d i f f e r e n t  i f  m o r e  t h a n  o n e
turned out to be suitable.
Conclusions
In summary, mutation analysis in gastrointestinal stromal
tumors gets increasing relevance for prognosis and treat-
ment strategies. Our interlaboratory trials have shown
that there is a broad range of possible pitfalls during the
different technical procedures and also in the interpreta-
tion of results. According to our results it is mandatory
that laboratories analysing GISTs should participate in
interlaboratory tests on a regular basis to minimize possi-
ble mistakes. Furthermore, centralisation of mutation
analysis in experienced laboratories with at least 50 ana-
lyzed tumors per year could help to increase the reliabil-
ity of results.
Methods
Design of study
The internal trial was performed in three steps to identify
potential pitfalls in methodology. Samples of paraffin-
embedded GISTs were obtained from all six pathology
archives of our panel in accordance with institutional
review board regulations of all six institutions. We started
with a set of extracted DNA samples from formalin-fixed
paraffin-embedded (FFPE) tissue which were sent to all
labs without any recommendations on how to perform
analysis and how to report the results. In a second step
Table 4: Proposal for reporting of mutational results in GISTs
Information required Optional information
- confirmation of the diagnosis GIST, based on morphological and 
immunohistochemical findings
- indicate the type of analysed material (primary tumor, metastasis, 
local relapse)
- indicate date of surgery if appropriate
- in case of a primary GIST indicate the individual risk classification 
according to consensus classification [27]
- according to [5]
- report on molecular findings for every exon analysed; indicate 
mutations on DNA and protein level in a standardized description 
according to [30]
- indicate homo-/hemizygous mutations
- indicate type of examination method (e.g. PCR and DNA 
sequencing)
- report on expected response to imatinib treatment based on the 
individual mutation type, according to recent recommendations;
- KIT exon 9: better response to 800 mg daily
- KIT exon 11: best response (at 400 mg daily)
- PDGFRA exon 18: according to special type of mutation (D842V 
resistant, deletions mostly responsive)
- report on prognostic relevance of the individual mutation type for 
clinical behaviour, according to recent data, e.g. [28]
- give an individual suggestion for adjuvant therapy, based on the 
individual mutation type and according to recent consensus 
recommendationsMerkelbach-Bruse et al. BMC Medical Genetics 2010, 11:106
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each lab provided two paraffin blocks leading to a series
of 12 blocks which were sent to each lab to perform the
whole protocol from extraction to the final result. A third
trial was added to compare the different primer sets for c-
KIT exon 11. It is well accepted that the different muta-
tional subtypes in this region are the most heterogeneous
ones. Primer sets for KIT exon 9 and PDGFRA exon 18
were not tested in this step. Comparison of the different
primer sets used within the panel for amplification of
these two hot spots led to the recommendation of two
different primer pairs each. Technical details for DNA
extraction, the different PCR approaches, cycling profiles
and bidirectional sequencing which are not described in
the following study steps are provided in the additional
files.
In detail, the following trials were performed:
1. Comparison of mutational analysis on extracted DNA 
samples
The first trial was performed in order to compare the
reproducibility of the mutation analysis and the reporting
between the different panel labs (referred to as Lab A to
Lab F in the following text) in a defined series of cases on
extracted DNA samples. A set of ten DNA samples (T1.1-
T1.10) extracted from formalin-fixed paraffin-embedded
(FFPE) tissue provided by Lab A was sent to the panel
laboratories B-F for the examination of the mutational
status of KIT and PDGFRA. The integrity of DNA was
confirmed by agarose gel electrophoresis. All samples
were previously examined for mutations in the relevant
exons. During the respective trial the mutational analysis
was repeated also by Lab A.
The set included samples with mutations in KIT exon 9
and 11, and PDGFRA  exon 18, and samples without
mutations in these exons. The samples were provided in
an anonymous fashion and each laboratory received
enough material to analyze all exons mentioned above.
Time limit for the reporting of results was two months,
results were reported without given reporting rules.
2. Mutation analysis from FFPE material
In the second trial, each group (Labs A-F) supplied two
paraffin blocks (T2.1-T2.12) for mutational analysis in
order to consider the heterogeneity of tissue blocks from
different sources and to compare the divergent extraction
protocols. The 12 blocks were collected in Lab A. H&E
stained sections from each block were evaluated by an
experienced pathologist (E.W.). In two samples a manual
microdissection was needed because these samples con-
tained both neoplastic and non-neoplastic tissue.
The whole set was sent to each panel laboratory to per-
form tissue sectioning, DNA extraction and mutational
analysis. Mutational data should be reported according to
the standard of the Human Genome Variation Society
(HGVS; http://www.hgvs.org). Again the time limit was
two months.
3. Comparison of different primer sets for KIT exon 11
The third trial was restricted to the mutational analysis of
KIT exon 11 to evaluate the quality and efficiency of dif-
ferent primer sets. A set of three DNA samples with dif-
ferent mutations in exon 11 (T3.1-T3.3) extracted from
FFPE tissue was analyzed in each panel laboratory (except
Lab B) using all different primer sets for exon 11 available
within the panel. Again, the samples were provided by
Lab A who repeated the analysis. The samples were pro-
vided in an anonymous fashion and each laboratory
received enough material to perform the mutational anal-
ysis for exon 11 with all primer combinations. Each labo-
ratory used its own amplification and sequencing
conditions. Reporting of mutational data and time limit
was the same as for the second trial.
External trial
In 2009 an external trial was conducted by the six panel
institutions. A pool of 30 paraffin embedded tissue blocks
was collected including cases with KIT exon 9, KIT exon
11 and PDGFRA exon 18 mutations as well as cases with-
out mutations in these three exons. Each panel lab pro-
vided blocks for this pool. All mutational data were cross-
validated by at least two of the panel labs. The first nine-
teen participating external labs received one H&E stained
section and three sections of five blocks to perform DNA
extraction and mutation analysis of KIT exon 9 and 11
and  PDGFRA  exon 18. Additionally, each external lab
received ten electropherograms from mutation analyses
performed previously on these three exons to test the
correct reporting of sequence data according to the
HGVS standard. The panel provided each participant
with the recommendation of a standard operating proce-
dure.
Additional material
Additional file 1 Methods used for mutation analysis by the panel 
labs. This file describes how to extract DNA from formalin-fixed paraffin-
embedded tissue, how PCR amplification and purification of PCR products 
prior to cycle sequencing can be performed and how cycle sequencing 
and precipitation of sequencing products should be done.
Additional file 2 Proposed standard operation procedure for testing 
and reporting of common KIT and PDGFRA mutations in GIST. The fun-
damental rules that should be the gold standard in every diagnostic molec-
ular pathology laboratory are explained. Furthermore, advices are given for 
the evaluation of the tissue area to be analyzed and about the procedure of 
sectioning and microdissecting of formalin-fixed, paraffin-embedded tissue 
blocks. Protocols are given for DNA extraction and quantification, for prim-
ers for KIT exons 9 and 11 and for PDGFRA exon 18 and for PCR amplifica-
tion. Another protocol explains how to purify the PCR fragments and how 
to perform cycle sequencing.
Additional file 3 Description of sequence data. This file explains how to 
report the sequence data. Several examples are given.Merkelbach-Bruse et al. BMC Medical Genetics 2010, 11:106
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